Cefazolin, a new cephalosporin derivative, was studied in the treatment of 105 hospitalized patients with a variety of infections including endocarditis, pneumonia, and urinary and soft tissue infections, and was found to be effective in 104 patients. Cefazolin was also tested in vitro and shown to be effective against staphylococci, pneumococci, Escherichia coli, Klebsiella sp., and Proteus mirabilis by agar dilution method. It was shown to produce high serum levels when administered in a 250-to 1,000-mg intramuscular dose and was well tolerated and free from renal toxicity. Comparison of the results of this study with those from our prior studies on cephaloridine revealed equivalent antibiotic potency, good tolerance to both the agents when given intramuscularly, superior, average blood levels with cefazolin, equal clinical efficacy, and absence of renal toxicity with cefazolin (unlike cephaloridine). Similarly, the results of treatment of pneumococcal pneumonia with intramuscular cefazolin were found to be superior to those for oral cephalexin.
Cefazolin is a new (available for study in the United States in 1972) parenteral cephalosporin derivative of 7-aminocephalosporanic acid shown in Japanese studies to be well tolerated and free from renal toxicity (19, 20) . It was found to shorten the treatment period in 34 patients with surgical infections (25) . This report deals with studies of the pharmacology, effectiveness, tolerance of cefazolin in the treatment of 105 hospitalized adult patients with endocarditis, pneumonia, urinary tract and soft tissue infections caused by susceptible pathogens, and the in vitro susceptibility of representative clinical isolates. Clinical observations were made at the Henry Ford Hospital, Detroit, Mich., and Medical College Hospital in Toledo, Ohio, and compared with those from our earlier studies of cephaloridine (45 patients) and cephalexin (41 patients).
MATERIALS AND METHODS
Antibacterial activity. The from resistant organisms. In concurrent studies with 30 gg of cephalothin per disk, similar results were found, indicating that either of these antibiotic disks would be suitable for cephalosporin susceptibility testing.
The average MIC of cephalothin, cephaloridine, and cefazolin was comparable for Staphylococcus aureus and S. pneumoniae (Table  1) . However, the average MIC for alpha streptococcus was 8 to 40 times greater for cefazolin than for cephalothin and cephaloridine, respectively. Cefazolin and cephaloridine were comparable and more active than cephalothin against E. coli and P. mirabilis ( Table 2 ). The average MIC of the three agents against indole-positive Proteus, Enterobacter, or Pseudomonas was 25 to 100 ,g/ml. Serum binding. Antimicrobial activity of the three antibiotics in broth and undiluted human serum indicated that cefazolin was 73% protein bound, cephalothin was 79% bound, and cephaloridine was only 11% bound. Kind et al., using the ultrafiltration method, reported binding of cephalothin and cephaloridine as 65 and 13%, respectively, in pooled human serum (13) . Nishida et al., with essentially the same method, showed a higher percentage of binding for cephalothin and cephaloridine (31%), and reported 74% for cefazolin sodium (19) .
Serum concentrations. Figure 4 illustrates the mean serum concentration as seen in patients given multiple intramuscular injections of cefazolin in doses of 250, 500, and 1,000 mg. A mean peak serum concentration of 30 (24) Enterobacter (24) 43.0 25.0 50 Pseudomonas (20) 100 100 ND a Not done.
The data for mean. serum concentration of cefazolin after multiple intramuscular injections in 20 patients, when compared with our previous studies with cephaloridine in 45 patients, suggests that cefazolin produced higher and more sustained average concentration than did cephaloridine (Fig. 5) .
Clinical results. The efficacy of cefazolin was evaluated in 105 patients with endocarditis, pneumonia, and urinary tract and soft tissue infections ( Tolerance and acceptability of intramuscular cefazolin and cephaloridine were equivalent, with little discomfort associated with intramuscular injection of these two agents. No cefazolin-treated patients exhibited renal toxicity. Two patients given cephaloridine developed drug-related reversible albuminuria and azotemia.
DISCUSSION
Cefazolin is a broad-spectrum bactericidal antibiotic which is effective in inhibiting growth ram-negative as well as offer several improvements over earlier cephaloositive pathogens. In the sporins. Cefazolin was found to be more active 105 (99%) hospitalized against E. coli and P. mirabilis than was s due to S. pneumoniae, cephalothin, and equivalent to cephaloridine. g staphylococci, alpha The mean serum concentrations were higher E. coli, Klebsiella sp., and more sustained than with cephalexin and te, and P. mirabilis im-cephaloridine. The drug was well tolerated both at with cefazolin.
intramuscularly and intravenously, unlike ,s are similar to those cephalothin which was shown to be associated other investigators (19) . with local irritation on intramuscular injection in antibiotic appears to and phlebitis when given intravenously (31) .
The (21) , and tubular necrosis (11, in the serum after multiple 26). In both the previous clinical reports by ions of 250, 500, and 1,oo-Japanese workers and the present study, all the parameters employed, including urine analysis, Group A beta hemolytic strepto- serum creatinine, and blood urea nitrogen, were normal throughout the therapy which, in some cases, extended for 6 weeks. Coombs positive hemolytic anemia, which has been observed with cephalothin (4, 5, 17), was also not seen with cefazolin. The other interesting observation is the absence of hypersensitivity reaction which is known to occur in some patients receiving other cephalosporins (10, 14) . However, the exclusion of patients known to have had previous penicillin reactions could account for this observation. The true incidence of hypersensitivity to cefazolin is not known. Cephalosporins are known to be effective in clinical infections caused by susceptible pathogens including S. aureus, S. pyogenes, S. pneumoniae, alpha streptococci, E. coli, Klebsiella sp., P. mirabilis, and H. influenzae (3, 6, 8, 9, 13, 24, 27, 30, 31, 32) . Shibata and Fujii have treated 34 patients with a variety of surgical infections, including perforative peritonitis, acute appendicitis, liver and biliary tract infections, and abscesses in the perianal region and abdominal wall, with good response (25) . Two patients who did not respond had infections due to P. vulgaris and P. aeruginosa. Only one patient developed a transient eruption. These results were confirmed in our present study with a larger number of patients and in two other recent studies done elsewhere (22, 23 
